TY - JOUR
T1 - Behavioral and Enhanced Perinatal Intervention (B-EPIC)
T2 - A randomized trial targeting tobacco use among opioid dependent pregnant women
AU - Fallin-Bennett, Amanda
AU - Lofwall, Michelle
AU - Waters, Teresa
AU - Nuzzo, Paul
AU - Barnett, Janine
AU - Ducas, Letitia
AU - McCubbin, Andrea
AU - Chavan, Niraj
AU - Blair, Lisa
AU - Ashford, Kristin
N1 - Funding Information:
This study was funded by the National Institute on Drug Abuse NIDA R34DA046005-02 .
Publisher Copyright:
© 2020
PY - 2020/12
Y1 - 2020/12
N2 - Background: Opioid use during pregnancy is a significant public health issue. The standard of care for treating opioid use disorder during pregnancy includes medications for opioid disorder (MOUD). However, tobacco use often goes unaddressed among pregnant women on MOUD. In 2018, our team received a National Institute on Drug Abuse (NIDA) funded R34 to conduct a three year-randomized trial to test the feasibility of a novel tobacco intervention for pregnant women receiving MOUD. Aims: The aims of this study are: (1) to determine the impact of the B-EPIC intervention on maternal tobacco use and stage of change; (2) to determine the impact of B-EPIC on tobacco-related maternal and infant health outcomes including gestational age at birth, birthweight, NAS diagnosis and severity, and number of ear and respiratory infections during the first six months; (3) to compare healthcare utilization and costs incurred by pregnant patients that receive the B-EPIC intervention versus TAU. Methods: We plan to enroll 100 pregnant women on MOUD for this randomized controlled trial (B-EPIC intervention n = 50 and treatment as usual n = 50). A major strength of this study is its wide range of health and economic outcomes assessed on mother, neonate and the infant. Conclusions: Despite the very high rates of smoking among pregnant women with OUD, there are few tobacco treatment interventions that have been tailored for this high - risk population. The overall goal of this study is to move towards a tobacco treatment standard for pregnant women receiving treatment for OUD.
AB - Background: Opioid use during pregnancy is a significant public health issue. The standard of care for treating opioid use disorder during pregnancy includes medications for opioid disorder (MOUD). However, tobacco use often goes unaddressed among pregnant women on MOUD. In 2018, our team received a National Institute on Drug Abuse (NIDA) funded R34 to conduct a three year-randomized trial to test the feasibility of a novel tobacco intervention for pregnant women receiving MOUD. Aims: The aims of this study are: (1) to determine the impact of the B-EPIC intervention on maternal tobacco use and stage of change; (2) to determine the impact of B-EPIC on tobacco-related maternal and infant health outcomes including gestational age at birth, birthweight, NAS diagnosis and severity, and number of ear and respiratory infections during the first six months; (3) to compare healthcare utilization and costs incurred by pregnant patients that receive the B-EPIC intervention versus TAU. Methods: We plan to enroll 100 pregnant women on MOUD for this randomized controlled trial (B-EPIC intervention n = 50 and treatment as usual n = 50). A major strength of this study is its wide range of health and economic outcomes assessed on mother, neonate and the infant. Conclusions: Despite the very high rates of smoking among pregnant women with OUD, there are few tobacco treatment interventions that have been tailored for this high - risk population. The overall goal of this study is to move towards a tobacco treatment standard for pregnant women receiving treatment for OUD.
KW - Opioid dependence
KW - Pregnancy
KW - tobacco Treatment
UR - http://www.scopus.com/inward/record.url?scp=85097060187&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097060187&partnerID=8YFLogxK
U2 - 10.1016/j.conctc.2020.100657
DO - 10.1016/j.conctc.2020.100657
M3 - Article
AN - SCOPUS:85097060187
VL - 20
M1 - 100657
ER -